Gold nanoparticles as antiangiogenic and antimetastatic agents.
angiogenesis
metastasis
nanomedicine
nanoparticles
oncology
theranostics
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
23
08
2022
revised:
27
10
2022
accepted:
08
11
2022
pubmed:
15
11
2022
medline:
3
2
2023
entrez:
14
11
2022
Statut:
ppublish
Résumé
Angiogenesis and metastasis are two interdependent cancer hallmarks, the latter of which is the key cause of treatment failure. Thus, establishing effective antiangiogenesis/antimetastasis agents is the final frontier in cancer research. Gold nanoparticles (GNPs) may provide disruptive advancements in this regard due to their intrinsic physical and physiological features. Here, we comprehensively discuss recent potential therapeutical strategies to treat angiogenesis and metastasis and present a critical review on the state-of-the-art in vitro and in vivo evaluations of the antiangiogenic/antimetastatic activity of GNPs. Finally, we provide perspectives on the contribution of GNPs to the advancement of cancer management.
Identifiants
pubmed: 36375738
pii: S1359-6446(22)00431-7
doi: 10.1016/j.drudis.2022.103438
pii:
doi:
Substances chimiques
Gold
7440-57-5
Antineoplastic Agents
0
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103438Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.